Trequinsin hydrochloride

Research use only, not for human use.

Trequinsin hydrochloride (HL 725) is a potent, cell-permeable, orally active inhibitor of cGMP-inhibited phosphodiesterase (PCE3 IC50=250 pM).

Trequinsin hydrochloride (HL 725) is a potent, cell-permeable, orally active inhibitor of cGMP-inhibited phosphodiesterase (PCE3 IC50=250 pM), inhibits arachidonic acid-induced aggregation of human platelets with IC50 of 50 pM; reduces systemic blood pressure in both normotensive and hypertensive animal models.Hypertension Discontinued.

Trequinsin hydrochloride exerts besides its cardiovascular and antihypertensive qualities very potent antiplatelet activities.Trequinsin hydrochloride is an efficacious agonist of [Ca2+]i. Cell Viability Assay Cell Line:Samples from healthy volunteer research donors with normal sperm motility parameters in agreement with World Health Organization 2010 criteria.Concentration:10 μM.Incubation Time:20 min.Result:Caused a concentration dependent increase in [Ca2+]i (EC50 = 6.4 μM [95% confidence interval (CI): 4.1-9.9 μM]).

——

HL 725

Angiogenesis

PDE

PDE

Cardiovascular Disease

Hypertension

78416-81-6

441.956

C24H28ClN3O3

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (141.42 mM)

CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2C)OC)OC)C.Cl

2,3,6,7-Tetrahydro-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-4H-pyrimido[6,1-a]isoquinolin-4-one hydrochloride

(-20℃)

With Ice Pack

≥ 2 years